2023 - rct - Pivotal Reference
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff AM et al.. N Engl J Med.
Bibliography For Semaglutide
Every Curated Peer-Reviewed Reference Indexed For This Compound. Each Citation Can Be Exported In BibTeX, RIS, EndNote, Or Plain Text.
Indexed Types:labelmonographpreprintrctstudy
2021 - rct - Pivotal Reference
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding JPH et al.. N Engl J Med.
2016 - rct - Pivotal Reference
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso SP et al.. N Engl J Med.
n.d. - study
Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
Unknown Authors.
n.d. - study
Activation of GLP-1R ameliorates alcohol withdrawal induced anxiety-like behavior by regulating neuronal mitochondrial quality control
Unknown Authors.
n.d. - study
Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.
Unknown Authors.
n.d. - study
Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.
Unknown Authors.
n.d. - study
Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis.
Unknown Authors.
n.d. - study
Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.
Unknown Authors.
n.d. - study
15-PGDH inhibition promotes muscle repair and strength recovery during GLP-1 receptor agonist-induced weight loss.
Unknown Authors.
n.d. - study
Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018-2024).
Unknown Authors.
n.d. - study
Glucagon-like peptide-1 receptor agonist, semaglutide, attenuates intravenous self-administration of fentanyl in female rats
Unknown Authors.
n.d. - study
Response to Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.
Unknown Authors.
n.d. - study
Evaluation of the Efficacy of Semaglutide Dose Escalation in Reducing HbA1c Levels and Insulin Dose in Type 2 Diabetes Patients: Real-World Semaglutide Data from Türkiye, SEMA-TR Study.
Unknown Authors.
n.d. - study
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.
Unknown Authors.
n.d. - study
Transient Hyperprolactinemia Associated With Semaglutide in a Patient With Hashimoto's Thyroiditis.
Unknown Authors.
n.d. - study
Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.
Unknown Authors.
n.d. - study
Comparative Effectiveness and Safety of Once-Weekly Injectable Semaglutide Versus Dulaglutide in Individuals with Type 2 Diabetes Managed in UK Primary Care: A Population-Based Cohort Study
Unknown Authors.
n.d. - study
Semaglutide Induces Oxidative Stress and Differentially Modulates mTOR-Dependent Growth and Invasion in Human Trophoblast Cell Models: Implications for Placental Function.
Unknown Authors.
n.d. - study
Two Doses to ICU or When Lactate Equals Glucose: Life-Threatening Lactic Acidosis due to Metformin After Initiation of Semaglutide.
Unknown Authors.
n.d. - study
Prolonged Dysesthesia After Massive Accidental Semaglutide Overdose: A Case Report.
Unknown Authors.
n.d. - study
Alopecia Risk With GLP‐1 Receptor Agonists: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS)
Unknown Authors.
n.d. - study
Projected reduction in major adverse cardiovascular events among high-risk U.S. adults with type 2 diabetes eligible for oral semaglutide: a SOUL trial-based analysis using NHANES (1988-2018) cycles.
Unknown Authors.
n.d. - study
Cross-sectional analysis of the reliability and engagement metrics of YouTube videos on semaglutide for weight loss.
Unknown Authors.
n.d. - study
Semaglutide in obesity and type 2 diabetes: A review of clinical trial evidence from 1 to 5 semaglutide treatment effect in people with obesity program.
Unknown Authors.
n.d. - study
A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.
Unknown Authors.
n.d. - study
Semaglutide-induced lean mass loss: clinical concern or physiological adaptation.
Unknown Authors.
n.d. - study
Not All Weight Loss Is Equal: Towards Muscle-Preserving Therapies in Obesity.
Unknown Authors.
n.d. - preprint
Plasma Proteomic Analysis of APOE ϵ4 Homozygotes Identifies Preclinical Alzheimer's Disease Alterations Potentially Modulated by Semaglutide
Unknown Authors.
n.d. - label
OZEMPIC (SEMAGLUTIDE) INJECTION, SOLUTION [NOVO NORDISK PHARMACEUTICAL INDUSTRIES, LP]
Unknown Authors.
n.d. - monograph
RxNorm 1991302 (Semaglutide)
Unknown Authors.